{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:08:19Z","timestamp":1794049699835,"version":"4.8.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40263-026-01301-z","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T18:18:02Z","timestamp":1779733082000},"page":"973-995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cannabidiol Use in Developmental and Epileptic Encephalopathies: A Syndrome- and Age-Stratified Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-7492","authenticated-orcid":false,"given":"Helen Michaela","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pandoara Eloa","family":"Oliveira Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Eduardo","family":"Trejo El\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Oliveira de Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Pinzon Blaskoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Ramon","family":"Fruett da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"4","key":"1301_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512\u201321. https:\/\/doi.org\/10.1111\/epi.13709.","journal-title":"Epilepsia"},{"issue":"1","key":"1301_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00546-6","volume":"10","author":"IE Scheffer","year":"2024","unstructured":"Scheffer IE, Zuberi S, Mefford HC, Guerrini R, McTague A. Developmental and epileptic encephalopathies. Nat Rev Dis Primers. 2024;10(1):61. https:\/\/doi.org\/10.1038\/s41572-024-00546-6. (Erratum in: Nat Rev Dis Primers. 2024 Sep 13;10(1):66. doi: 10.1038\/s41572-024-00558-2).","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1301_CR3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/epi.17866","volume":"65","author":"J Sullivan","year":"2024","unstructured":"Sullivan J, Ben\u00edtez A, Roth J, Andrews JS, Shah D, Butcher E, et al. A systematic literature review on the global epidemiology of Dravet syndrome and Lennox-Gastaut syndrome: Prevalence, incidence, diagnosis, and mortality. Epilepsia. 2024;65(5):1240\u201363. https:\/\/doi.org\/10.1111\/epi.17866. (Epub 2024 Jan 22).","journal-title":"Epilepsia"},{"issue":"9","key":"1301_CR4","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1007\/s00431-024-05677-2","volume":"183","author":"JF Velarde-Garc\u00eda","year":"2024","unstructured":"Velarde-Garc\u00eda JF, G\u00fceita-Rodr\u00edguez J, Jim\u00e9nez-Antona C, Garc\u00eda-Bravo C, Aledo-Serrano \u00c1, G\u00f3mez-S\u00e1nchez SM, et al. The impact of developmental and epileptic encephalopathies on families: a qualitative study. Eur J Pediatr. 2024;183(9):4103\u201310. https:\/\/doi.org\/10.1007\/s00431-024-05677-2. (Epub 2024 Jul 5).","journal-title":"Eur J Pediatr"},{"issue":"1","key":"1301_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1684\/epd.2021.1244","volume":"23","author":"S Raga","year":"2021","unstructured":"Raga S, Specchio N, Rheims S, Wilmshurst JM. Developmental and epileptic encephalopathies: recognition and approaches to care. Epileptic Disord. 2021;23(1):40\u201352. https:\/\/doi.org\/10.1684\/epd.2021.1244.","journal-title":"Epileptic Disord"},{"key":"1301_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.pediatrneurol.2025.04.010","volume":"168","author":"D Samanta","year":"2025","unstructured":"Samanta D, Bhatia S, Hunter SE, Rao CK, Xiong K, Karakas C, et al. Current and emerging precision therapies for developmental and epileptic encephalopathies. Pediatr Neurol. 2025;168:67\u201381. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2025.04.010. (Epub 2025 Apr 25).","journal-title":"Pediatr Neurol"},{"issue":"17","key":"1301_CR7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","volume":"78","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78(17):1791\u2013804. https:\/\/doi.org\/10.1007\/s40265-018-0992-5.","journal-title":"Drugs"},{"key":"1301_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.seizure.2025.10.001","volume":"133","author":"A Saranti","year":"2025","unstructured":"Saranti A, Dragoumi P, Pavlogiannis K, Pavlou E, Zafeiriou D. Efficacy and safety of cannabidiol in children with developmental and epileptic encephalopathies: a systematic review. Seizure. 2025;133:114\u201327. https:\/\/doi.org\/10.1016\/j.seizure.2025.10.001.","journal-title":"Seizure"},{"issue":"3","key":"1301_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","volume":"35","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, et al. Highly purified cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet Syndrome and Lennox-Gastaut Syndrome. CNS Drugs. 2021;35(3):265\u201381. https:\/\/doi.org\/10.1007\/s40263-021-00807-y.","journal-title":"CNS Drugs"},{"key":"1301_CR10","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023."},{"key":"1301_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"1301_CR12","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013."},{"key":"1301_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"10","key":"1301_CR14","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127\u201333. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099.","journal-title":"JBI Evid Synth."},{"issue":"3","key":"1301_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.11124\/JBIES-24-00103","volume":"23","author":"TH Barker","year":"2025","unstructured":"Barker TH, Hasanoff S, Aromataris E, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for cohort studies. JBI Evid Synth. 2025;23(3):441\u201353. https:\/\/doi.org\/10.11124\/JBIES-24-00103.","journal-title":"JBI Evid Synth"},{"issue":"4","key":"1301_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2013.285063","volume":"311","author":"X Sun","year":"2014","unstructured":"Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users\u2019 guide to the medical literature. JAMA. 2014;311(4):405\u201311. https:\/\/doi.org\/10.1001\/jama.2013.285063.","journal-title":"JAMA"},{"issue":"32","key":"1301_CR17","doi-asserted-by":"publisher","first-page":"E901","DOI":"10.1503\/cmaj.200077","volume":"192","author":"M Borenstein","year":"2020","unstructured":"Borenstein M, van der Heijden GJMG, Dahabreh IJ, Sun X, Sauerbrei W, Walsh M, et al. Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020;192(32):E901\u20136. https:\/\/doi.org\/10.1503\/cmaj.200077.","journal-title":"CMAJ"},{"key":"1301_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110426","volume":"169","author":"E Aizara","year":"2025","unstructured":"Aizara E, Robin TV, Hanna L, Amy UL, Brooke M, Rebecca P, et al. Adjunctive use of cannabidiol in pediatric drug-resistant epilepsy: a retrospective multicenter analysis. Epilepsy Behav. 2025;169:110426. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110426. (Epub 2025 Apr 26).","journal-title":"Epilepsy Behav"},{"issue":"8","key":"1301_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082120","volume":"15","author":"L Brstilo","year":"2023","unstructured":"Brstilo L, Reyes Valenzuela G, Caraballo R, P\u00e9rez Montilla C, Garc\u00eda Bournissen F, C\u00e1ceres Guido P, et al. Real-world evidence of factors affecting cannabidiol exposure in children with drug-resistant developmental and epileptic encephalopathies. Pharmaceutics. 2023;15(8):2120. https:\/\/doi.org\/10.3390\/pharmaceutics15082120.","journal-title":"Pharmaceutics"},{"key":"1301_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1616480","volume":"16","author":"A Butera","year":"2025","unstructured":"Butera A, Spoto G, Ceraolo G, Grella M, Giunta I, Albertini ML, et al. Efficacy and safety of cannabidiol in a single-center pediatric drug-resistant epilepsy cohort: a retrospective study. Front Neurol. 2025;16:1616480. https:\/\/doi.org\/10.3389\/fneur.2025.1616480.","journal-title":"Front Neurol"},{"key":"1301_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.seizure.2021.10.002","volume":"92","author":"R Caraballo","year":"2021","unstructured":"Caraballo R, Valenzuela GR. Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: a study of eight patients. Seizure. 2021;92:238\u201343. https:\/\/doi.org\/10.1016\/j.seizure.2021.10.002. (Epub 2021 Oct 3).","journal-title":"Seizure"},{"key":"1301_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.seizure.2022.01.001","volume":"95","author":"R Caraballo","year":"2022","unstructured":"Caraballo R, Reyes G, Demirdjian G, Huaman M, Gutierrez R. Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy. Seizure. 2022;95:56\u201363. https:\/\/doi.org\/10.1016\/j.seizure.2022.01.001. (Epub 2022 Jan 4).","journal-title":"Seizure"},{"issue":"6","key":"1301_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.5863\/1551-6776-27.6.558","volume":"27","author":"NT Cohen","year":"2022","unstructured":"Cohen NT, Bahar B, Conry JA, Schreiber JM. Variability in serum concentrations and clinical response in artisanal versus pharmaceutical cannabidiol treatment of pediatric pharmacoresistant epilepsy. J Pediatr Pharmacol Ther. 2022;27(6):558\u201363. https:\/\/doi.org\/10.5863\/1551-6776-27.6.558.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"1301_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.637801","volume":"12","author":"M Contin","year":"2021","unstructured":"Contin M, Mohamed S, Santucci M, Lodi MAM, Russo E, Mecarelli O, et al. Cannabidiol in pharmacoresistant epilepsy: clinical pharmacokinetic data from an expanded access program. Front Pharmacol. 2021;12:637801. https:\/\/doi.org\/10.3389\/fphar.2021.637801.","journal-title":"Front Pharmacol"},{"key":"1301_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00829","volume":"11","author":"G D'Onofrio","year":"2020","unstructured":"D\u2019Onofrio G, Kuchenbuch M, Hachon-Le Camus C, Desnous B, Staath V, Napuri S, et al. Slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study. Front Neurol. 2020;11:829. https:\/\/doi.org\/10.3389\/fneur.2020.00829.","journal-title":"Front Neurol"},{"issue":"3","key":"1301_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(15)00379-8.","journal-title":"Lancet Neurol"},{"issue":"21","key":"1301_CR27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611618.","journal-title":"N Engl J Med"},{"issue":"20","key":"1301_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018;378(20):1888\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1714631.","journal-title":"N Engl J Med"},{"key":"1301_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","volume":"86","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, et al. Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131\u20137. https:\/\/doi.org\/10.1016\/j.yebeh.2018.05.013. (Epub 2018 Jul 11).","journal-title":"Epilepsy Behav"},{"issue":"14","key":"1301_CR30","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204\u201311. https:\/\/doi.org\/10.1212\/WNL.0000000000005254. (Epub 2018 Mar 14).","journal-title":"Neurology"},{"key":"1301_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109904","volume":"157","author":"M Elbadri","year":"2024","unstructured":"Elbadri M, Bose S, Elkider M, Hayton T, mccorry D, Sumangala S, et al. Is adjunctive cannabidiol effective in controlling seizures for adult patients with Lennox-Gastaut Syndrome?\u2014a single centre long term follow up study. Epilepsy Behav. 2024;157:109904. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109904. (Epub 2024 Jun 21).","journal-title":"Epilepsy Behav"},{"key":"1301_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2024.100731","volume":"29","author":"C Eltze","year":"2024","unstructured":"Eltze C, Alshehhi S, Ghfeli AA, Vyas K, Saravanai-Prabu S, Gusto G, et al. The use of cannabidiol in patients with Lennox-Gastaut syndrome and Dravet syndrome in the UK Early Access Program: a retrospective chart review study. Epilepsy Behav Rep. 2024;29:100731. https:\/\/doi.org\/10.1016\/j.ebr.2024.100731.","journal-title":"Epilepsy Behav Rep"},{"key":"1301_CR33","unstructured":"Garza Morales SJ, Benavides Aguilar O, Bastida Mercado E. Use of cannabidiol (RSHO) in the treatment of refractory epilepsy (Lennox-Gastaut syndrome), experience of 38 cases. Epilepsia 2017; 58 (Suppl. 5):S53. (Conference Abstract)."},{"issue":"8","key":"1301_CR34","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351. https:\/\/doi.org\/10.1111\/epi.13060. (Epub 2015 Jun 26).","journal-title":"Epilepsia"},{"key":"1301_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.673135","volume":"12","author":"LF Iannone","year":"2021","unstructured":"Iannone LF, Arena G, Battaglia D, CBD LICE Italy Study Group, et al. Results from an Italian expanded access program on cannabidiol treatment in highly refractory Dravet Syndrome and Lennox-Gastaut Syndrome. Front Neurol. 2021;12:673135. https:\/\/doi.org\/10.3389\/fneur.2021.673135.","journal-title":"Front Neurol"},{"issue":"7","key":"1301_CR36","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1111\/epi.18378","volume":"66","author":"E Cerulli Irelli","year":"2025","unstructured":"Cerulli Irelli E, Mazzeo A, Caraballo RH, et al. Expanding the therapeutic role of highly purified cannabidiol in monogenic epilepsies: a multicenter real-world study. Epilepsia. 2025;66(7):2253\u201367. https:\/\/doi.org\/10.1111\/epi.18378.","journal-title":"Epilepsia"},{"key":"1301_CR37","doi-asserted-by":"publisher","unstructured":"Jang HN, Kim MJ, Yum MS, et al. Cannabidiol treatment for lennox-gastaut syndrome at a single tertiary center in South Korea. Ann Child Neurol. 2023;31(1):20\u201326. https:\/\/doi.org\/10.26815\/acn.2022.00255","DOI":"10.26815\/acn.2022.00255"},{"issue":"5","key":"1301_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3988\/jcn.2022.18.5.547","volume":"18","author":"SH Kim","year":"2022","unstructured":"Kim SH, Choi HS, Koo CM, et al. Effects of cannabidiol on adaptive behavior and quality of life in pediatric patients with treatment-resistant epilepsy. J Clin Neurol. 2022;18(5):547\u201352. https:\/\/doi.org\/10.3988\/jcn.2022.18.5.547.","journal-title":"J Clin Neurol"},{"issue":"50","key":"1301_CR39","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e427","volume":"35","author":"CM Koo","year":"2020","unstructured":"Koo CM, Kim SH, Lee JS, et al. Cannabidiol for treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea. J Korean Med Sci. 2020;35(50):e427. https:\/\/doi.org\/10.3346\/jkms.2020.35.e427. (Published 2020 Dec 28).","journal-title":"J Korean Med Sci"},{"issue":"3","key":"1301_CR40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/epi4.12411","volume":"5","author":"M Kuchenbuch","year":"2020","unstructured":"Kuchenbuch M, D\u2019Onofrio G, Chemaly N, Barcia G, Teng T, Nabbout R. Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy. Epilepsia Open. 2020;5(3):496\u2013500. https:\/\/doi.org\/10.1002\/epi4.12411. (Published 2020 Jul 1).","journal-title":"Epilepsia Open"},{"issue":"2","key":"1301_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/epi4.12699","volume":"8","author":"F K\u00fchne","year":"2023","unstructured":"K\u00fchne F, Becker LL, Bast T, et al. Real-world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study. Epilepsia Open. 2023;8(2):360\u201370. https:\/\/doi.org\/10.1002\/epi4.12699.","journal-title":"Epilepsia Open"},{"key":"1301_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","volume":"154","author":"LC Laux","year":"2019","unstructured":"Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results. Epilepsy Res. 2019;154:13\u201320. https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.03.015.","journal-title":"Epilepsy Res"},{"key":"1301_CR43","first-page":"A142","volume":"31","author":"J Serra L\u00f3pez-Matencio","year":"2024","unstructured":"Serra L\u00f3pez-Matencio J, Alvarez Yuste A, Ramirez Herraiz E, et al. 4CPS-189 local experience on the use of cannabidiol for the treatment of refractory epilepsy: safety and efficacy on a 10 patient cohort. Eur J Hosp Pharm. 2024;31:A142\u20133.","journal-title":"Eur J Hosp Pharm"},{"key":"1301_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pediatrneurol.2025.04.015","volume":"169","author":"A Lusawat","year":"2025","unstructured":"Lusawat A, Khongkhatithum C, Suwannachote S, et al. National multicenter cohort study: adjunctive cannabidiol-enriched cannabis oil for pediatric drug-resistant epilepsy treatment in Thailand. Pediatr Neurol. 2025;169:59\u201368. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2025.04.015.","journal-title":"Pediatr Neurol"},{"key":"1301_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2024.100720","volume":"28","author":"Y Masataka","year":"2024","unstructured":"Masataka Y, Miki N, Akino K, Yamamoto H, Takumi I. Case reports of identical twins with developmental and epileptic encephalopathy with STXBP1 gene mutations for whom different CBD supplementations were markedly effective. Epilepsy Behav Rep. 2024;28:100720. https:\/\/doi.org\/10.1016\/j.ebr.2024.100720. (Published 2024 Oct 24).","journal-title":"Epilepsy Behav Rep"},{"issue":"9","key":"1301_CR46","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/acn3.621","volume":"5","author":"B McCoy","year":"2018","unstructured":"McCoy B, Wang L, Zak M, et al. A prospective open-label trial of a CBD\/THC cannabis oil in Dravet syndrome. Ann Clin Transl Neurol. 2018;5(9):1077\u201388. https:\/\/doi.org\/10.1002\/acn3.621. (Published 2018 Aug 1).","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"1301_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","volume":"77","author":"I Miller","year":"2020","unstructured":"Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(5):613\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0073.","journal-title":"JAMA Neurol"},{"key":"1301_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.seizure.2023.05.003","volume":"110","author":"R Nabbout","year":"2023","unstructured":"Nabbout R, Arzimanoglou A, Auvin S, et al. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome. Seizure. 2023;110:78\u201385. https:\/\/doi.org\/10.1016\/j.seizure.2023.05.003.","journal-title":"Seizure"},{"issue":"3","key":"1301_CR49","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neurol.2023.07.012","volume":"180","author":"M Perriguey","year":"2024","unstructured":"Perriguey M, Succar ME, Cl\u00e9ment A, et al. High-purified cannabidiol efficacy and safety in a cohort of adult patients with various types of drug-resistant epilepsies. Rev Neurol (Paris). 2024;180(3):147\u201353. https:\/\/doi.org\/10.1016\/j.neurol.2023.07.012.","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"1301_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40272-019-00341-x","volume":"21","author":"N Pietrafusa","year":"2019","unstructured":"Pietrafusa N, Ferretti A, Trivisano M, et al. Purified cannabidiol for treatment of refractory epilepsies in pediatric patients with developmental and epileptic encephalopathy. Paediatr Drugs. 2019;21(4):283\u201390. https:\/\/doi.org\/10.1007\/s40272-019-00341-x.","journal-title":"Paediatr Drugs"},{"key":"1301_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejpn.2019.12.024","volume":"25","author":"K Poisson","year":"2020","unstructured":"Poisson K, Wong M, Lee C, Cilio MR. Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: an open-label, prospective, interventional study. Eur J Paediatr Neurol. 2020;25:77\u201381. https:\/\/doi.org\/10.1016\/j.ejpn.2019.12.024.","journal-title":"Eur J Paediatr Neurol"},{"key":"1301_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","volume":"45","author":"CA Press","year":"2015","unstructured":"Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49\u201352. https:\/\/doi.org\/10.1016\/j.yebeh.2015.02.043.","journal-title":"Epilepsy Behav"},{"key":"1301_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110590","volume":"171","author":"G Reyes Valenzuela","year":"2025","unstructured":"Reyes Valenzuela G, Espeche A, Fortini S, et al. A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies. Epilepsy Behav. 2025;171:110590. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110590.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1301_CR54","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1089\/can.2022.0255","volume":"9","author":"A Riva","year":"2024","unstructured":"Riva A, D\u2019Onofrio G, Pisati A, et al. Cannabidiol add-on in glycosylphosphatidylinositol-related drug-resistant epilepsy. Cannabis Cannabinoid Res. 2024;9(4):990\u20135. https:\/\/doi.org\/10.1089\/can.2022.0255.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"1301_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-018-0589-2","volume":"33","author":"TT Sands","year":"2019","unstructured":"Sands TT, Rahdari S, Oldham MS, Caminha Nunes E, Tilton N, Cilio MR. Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an expanded access program in the US. CNS Drugs. 2019;33(1):47\u201360. https:\/\/doi.org\/10.1007\/s40263-018-0589-2.","journal-title":"CNS Drugs"},{"key":"1301_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.seizure.2021.05.014","volume":"91","author":"K Silvennoinen","year":"2021","unstructured":"Silvennoinen K, Ritter LM, Nashef L, et al. Two-center experience of cannabidiol use in adults with Dravet syndrome. Seizure. 2021;91:5\u20138. https:\/\/doi.org\/10.1016\/j.seizure.2021.05.014.","journal-title":"Seizure"},{"key":"1301_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110302","volume":"166","author":"A Strzelczyk","year":"2025","unstructured":"Strzelczyk A, Schubert-Bast S, von Podewils F, et al. Real-world experience of cannabidiol in conjunction with clobazam for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome: results from a retrospective multicentre chart review in Germany. Epilepsy Behav. 2025;166:110302. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110302.","journal-title":"Epilepsy Behav"},{"issue":"10125","key":"1301_CR58","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(18)30136-3.","journal-title":"Lancet"},{"issue":"1","key":"1301_CR59","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/epi.13617","volume":"58","author":"L Treat","year":"2017","unstructured":"Treat L, Chapman KE, Colborn KL, Knupp KG. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia. 2017;58(1):123\u20137. https:\/\/doi.org\/10.1111\/epi.13617.","journal-title":"Epilepsia"},{"key":"1301_CR60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pediatrneurol.2023.10.012","volume":"150","author":"M Tzadok","year":"2024","unstructured":"Tzadok M, Gur-Pollack R, Florh H, et al. Real-life experience with purified cannabidiol treatment for refractory epilepsy: a multicenter retrospective study. Pediatr Neurol. 2024;150:91\u20136. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.10.012.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"1301_CR61","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/epi4.70078","volume":"10","author":"A Vignoli","year":"2025","unstructured":"Vignoli A, Prato G, Alfei E, et al. Is highly purified cannabidiol a treatment opportunity for drug-resistant epilepsy in subjects with typical Rett syndrome and CDKL5 deficiency disorder? Epilepsia Open. 2025;10(4):1111\u20139. https:\/\/doi.org\/10.1002\/epi4.70078.","journal-title":"Epilepsia Open."},{"issue":"Pt A","key":"1301_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108958","volume":"137","author":"V Villanueva","year":"2022","unstructured":"Villanueva V, Garc\u00eda-Ron A, Smeyers P, et al. Outcomes from a Spanish expanded access program on cannabidiol treatment in pediatric and adult patients with epilepsy. Epilepsy Behav. 2022;137(Pt A):108958. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108958.","journal-title":"Epilepsy Behav"},{"issue":"5","key":"1301_CR63","volume":"68","author":"M Zilmer","year":"2021","unstructured":"Zilmer M, Olofsson K. Cannabidiol treatment of severe refractory epilepsy in children and young adults. Dan Med J. 2021;68(5):A07200527 (Published 2021 Apr 28).","journal-title":"Dan Med J"},{"issue":"1","key":"1301_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03972-9","volume":"23","author":"Z Goudarzi","year":"2025","unstructured":"Goudarzi Z, Lotfi F, Shahtaheri RS, Moradi N, Taghizadeh M, Keshavarz K. Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis. BMC Med. 2025;23(1):135. https:\/\/doi.org\/10.1186\/s12916-025-03972-9. (Published 2025 Mar 5).","journal-title":"BMC Med"},{"issue":"11","key":"1301_CR65","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s40273-020-00945-z","volume":"38","author":"EE Neuberger","year":"2020","unstructured":"Neuberger EE, Carlson JJ, Veenstra DL. Cost-effectiveness of cannabidiol adjunct therapy versus usual care for the treatment of seizures in Lennox-Gastaut Syndrome. Pharmacoeconomics. 2020;38(11):1237\u201345. https:\/\/doi.org\/10.1007\/s40273-020-00945-z.","journal-title":"Pharmacoeconomics"},{"key":"1301_CR66","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.2147\/NDT.S529751","volume":"21","author":"F Villani","year":"2025","unstructured":"Villani F, Dono F, Operto FF, et al. Cenobamate for difficult-to-treat epilepsy - selected case vignettes. Neuropsychiatr Dis Treat. 2025;21:2437\u201348. https:\/\/doi.org\/10.2147\/NDT.S529751. (Published 2025 Nov 5).","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1301_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.70191","author":"E Wirrell","year":"2025","unstructured":"Wirrell E, Wheless J, Perry MS, et al. Stiripentol use in Dravet syndrome patients in the USA: results of a real-world study. Epilepsia Open. 2025. https:\/\/doi.org\/10.1002\/epi4.70191. (Published online November 30,).","journal-title":"Epilepsia Open"},{"key":"1301_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2025.107687","volume":"218","author":"P Parra-D\u00edaz","year":"2025","unstructured":"Parra-D\u00edaz P, Gil-Nagel A, Rom\u00e1n IS, et al. Fenfluramine for developmental and epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS): an exploratory study. Epilepsy Res. 2025;218:107687. https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107687.","journal-title":"Epilepsy Res"},{"issue":"6","key":"1301_CR69","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/epi.16546","volume":"61","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61(6):1090\u20138. https:\/\/doi.org\/10.1111\/epi.16546.","journal-title":"Epilepsia"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01301-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01301-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01301-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:47:28Z","timestamp":1782380848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01301-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1301"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01301-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to report. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"HMO contributed to the conception and design of the study, acquisition and analysis of data, and drafting significant portions of the manuscript and figures. PEOF contributed to the acquisition and analysis of data and the drafting of significant portions of the figures. JETE contributed to the acquisition of data. GOP contributed to the acquisition and analysis of data. PRFC and APB contributed to the drafting of significant portions of the manuscript. All authors have read and approve the final manuscript and agree to be accountable for the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The data that support the findings of this study are available from the corresponding author upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The statistical code used to perform the meta-analyses is publicly available in an open repository at:\n                      \n                      . The repository includes the scripts required to reproduce the main analyses and figures. Data used in the analyses are available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}